Cell Genesys Report issue

Contributed to NME For profit Phase 1 Phase 2 Phase 3
Founded: Hayward CA United States (1988)
Status: Acquired by Genzyme (1999) → now Sanofi-Aventis (2011)

Organization Overview

First Clinical Trial
1998
NCT00140374
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2008

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 2)

Carcinoma, Transitional Cell (Phase 1)

Leukemia (Phase 2)

Leukemia, Myeloid (Phase 2)

Leukemia, Myeloid, Acute (Phase 2)

Lung Neoplasms (Phase 2)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Pancreatic Neoplasms (Phase 2)

Prostatic Neoplasms (Phase 3)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 16
  • # of Trial APIs: 15